




BIBLIOGRAFIA



Adamczack M, Gross ML, Krtil J, Koch A, Tyralla K, Amann K and Ritz E (2003). Reversal of glomerulosclerosis after High-dose Enalapril Treatment in subtotally nephrectomized rats. *J. Am. Soc. Nephrol.* 14:2833-2842.

Afzali B, Haydar A, Vinen K and Goldsmit D. (2004) Beneficial effects of statins on the kidney: The evidence moves from mouse to man. *Nephrol. Dial. Transplant.* 19 (5):1032-6.

Agarwal R. (2006) Effects of statins on renal function. *Amj. Cardiol.* 97: 748-755.

Al-Shebeb T, Frohlich J, and Magil AB. (1988). Glomerular disease in hypercholesterolemic guinea pigs, a pathogenic study. *Kidney Int.* 33: 498-507.

Anitschow N and Chatalow A. (1913) Uber experimentelle Cholesterin-statose und ihre Bedeutung fur die Entstehung einiger phatologischer Prozesse. *Zentralb. Allghm. Pathol. Anat.* 14:1-9.

Aragoncillo P, Maeso R, Vazquez-PérezS, Navarro-Cid J, Ruilope LM, Díaz C.(2000). The protective role of atorvastatin on function structure and ultrastructure in the aorta of dyslipemic rabbits. *Virchows Archiv.* 437:545-54.

Atchley DH, Lopes-Virella MF, Zheng D, Kenny D and Virella G. (2002). Oxidized LDL-antioxidized LDL immune complexes and diabetic nephropathy. *Diabetologia* .45:1562-1571.

Athyros VG, Mikhailidis DP, Papageorgiou AA, Symeonidis AN, Pehlivanidis AM, Bouloukos V I and Elisaf M. (2004) The effect of statins versus untreated dislipemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. *Journal of clinical Pathology*. 57:728-734.

Aviram M, Danker G, Cogan U, Hochgraf E, Brook JG. (1992). Lovastatin inhibits low-density lipoprotein oxidation and alters its fluidity and uptake by macrophages: In vitro and in vivo studies. *Metabolism*.41:414-9.

Avram M.M. (1989). Similarities between glomerulosclerosis and atherosclerosis in human renal biopsy specimens, a role for lipoproteins glomerulopathy. *Am J. Med.* 87: 39N-41N.

Awrich P, Nagde G.and Wolf B. (1983) Fatty liver and kidney syndrome in chickens as an animal model for Reye´s syndrome. *Journal of Pediatric Gastroenterology and Nutrition* 2:683-692 .

Ayala I, García Pérez B, Domenech G, Montes AM, Ortega N, Ortega JV, Sánchez Polo MT.(2003) Uso del pollo como modelo experimental en arteriosclerosis. *An. Vet.(Murcia)*19:99-108.

Ayala I, García Pérez B, Doménech G, Sánchez Polo MT, Ortega JV, Castells MT. (2004). Estudio comparativo de diversos métodos de aterogénesis experimental en el pollo. *An. Vet. Murcia*. 20:123-127.

Ayala, I, Gutierrez-Panizo C, De Membiela, F., Montes, A. (2000). El uso de modelos animales en el estudio de la arteriosclerosis humana. *Rev. Exp. Anim.* 10-11(1-2): 53-58.

Ayala I, García Pérez B, Domenech G, Castells MT., Valdés M. (2005). Use of the chicken as an Experimental Model in Atherosclerosis. *Aviam and poultry biology reviews* 16(3):151-159.

Badimon JJ, Badimon L, Turito VT, Fuster V. Platelet deposition at high shear rates is enhanced by high plasma cholesterol levels. *Artheroscl. Thromb.* 11:395-402.

Ballantyne, CM., Corsini, A., Davidson, MH., Holdaas, H., Jacobson, TA., Leitersdorf, E., Marz, W., Reckless, JP and Stevin, EA. (2003). Risk of myopathy with statin therapy in high risk patients. *Arch. Intern. Med.* 163:553.

Bauman H, Gauldie J. (1994) The acute phase response. *Inmunol. Today*. 15:74-80.

Bayes-Genis A, Conover CA, Schwartz RS. (2000) The insulin-like growth factor axis: A review of atherosclerosis and restenosis. *Circ. Res.* 86:125-130.

Becerra DG, Mandarín-de-Lacerda CA. (2005) Beneficial effects of simvastatin and pravastatin treatment on adverse cardiac remodelling and glomeruly lost in spontaneously hipertensive rats. *Clin Sci.* 108(4):349-55.

Bellosta S, Bernini F, Ferri N, Quarato P, Canavesi M, Arnaboldi L. (1998). Direct vascular affects of HMG Co-A reductasa inhibitors. *Atherosclerosis.* 137:S101-S9.

Berberian PA, Myers W, Tytell M, Challa M, Bond MG. (1990) Immunohistochemical localization of Heat Shock protein-70 in normal appearing and atherosclerotic specimens of human arteries. *Am. J. Pathol.* 136:71-80.

Bianchi S, Bagazzy R, Caiazza A. (2003). A controlled prospective study of the effects of atorvastatina on proteinuria and progression of kidney disease. *Am. J. Kidney Dis.* 41:565-570.

Blanco-Colio LM, Tuñón J, Martín-Ventura LJ and Egido J. (2003) Antiinflammatory and inmunomodulatory effects of statins. *Kidney international.* Vol.63:12-23.

Black DM., Backer Arkema RG .(1998) An overview of the clinical safety profile of atorvastatina, a new HMGC_o-a reductasa inhibitor. *Arch intern med.* 158:577-84.

Blanco-Colio LM, Martín Ventura JL. (2003) Efectos antiinflamatorios de la atorvastatina. *Clin. e invest. en arteriosclerosis* Vol 15:(2) 15-23

Boffa JJ, Ying Lu, Placier S, Stefanski A and Dussaule JC. (2003) Regression of renal vascular and glomerular fibrosis: Role of angiotensin II Receptor Antagonism and matrix metalloproteinases J. AM. Soc. Nephrol 14: 1132-1144.

Brown AS, Bakker-Arkema RG, Yelen L. (1998) Treating patients with documented atherosclerosis to National Cholesterol education program recommended low density lipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin. J Am Cardiol. 32:665

Brown BG, Fuster V. (1996). Impact of management in stabilization of coronary disease, in Atherosclerosis and coronary heart disease, edited by Fuster V, Ross R, Topol EJ, Philadelphia. Lippincott-Raven. 191-205.

Brown DL, Hibbs MS, Kearney M, Loushin C, Isner JM. (1995) Identification of 92 - KD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with sustable angina. Circulation 1995; 91: 2125 - 2131.

Brown MS, Goldstein JL. (1986). A receptor mediated pathway for cholesterol homeostasis. Science. 232:34-47.

Buemi M., Senatore M., Corica F, Aloisi C and Romeo A. (2001) Statins and progresive renal disease. Medicinal research reviews Vol 22. 1:76-84.

Buemi M., Allegra, A, Corica S and Aloisi C. (1999). Proapoptoic effect of fluvastatin on human muscle cells. Eur. J. Pharmacol. 370:201-203.

Buemi M., Allegra A, Corica S, Aloisi C, Giacobbe MS, Pettinato C, Corsonello A, Senatore M and Frisina N. (2000) Effect of fluvastatin on proteinuria in patients with IgA nephropathy. *Clin. Pharmacol. Ther.* 67:427-431.

Carda Aparici P, García Partida P. (1965). Efectos de dietas hipergrasas en gallinas ponedoras. Su corrección con flavonas. *Zootecnia* 14(4):1-15

Casey RG, Joyce M, Roche-Nagle G, Chen G and Bouchier-Hayes. (2005) Pravastatin modulates early diabetic nephropathy in an experimental model of diabetic renal disease. *J. Surg. Res.* 132; (2): 176-81.

Castelao Martínez A. (2005) Seguridad de las estatinas en el paciente con insuficiencia renal. *Clin. Invest. Arterioscl.* 17(2):83-92.

Chait A, Heinecke JW (1994) Lipoprotein modification: Cellular mechanisms. *Curr. Opin. Lipidol.* 5:363-370.

Chang JW, Yang WS, Min WK. (2002). Effects of simvastatin on high-sensitivity C-reactive protein and serum albumin in hemodialysis patients. *Am J. Kidney Dis* 39:1213-1217.

Chong PH, Seeger JD and Franklin C. (2001). Clinically relevant differences between statins: implication for therapeutic selection. *Am. J. Med.* 111:390-400.

Crisby, M; Nordin-Fredriksson G, Shah P, Yano J, Zhu J and Nilsson J. (2001). Pravastatin treatment increases collagen content and decreases

lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques. Implication for plaque stabilisation. *Circulation*. 20:927-932

Dangas G, Badimon JJ, Smith DA . (1999). Pravastatin therapy in hyperlipidemia: Effects on thrombus formation and the systemic hemostatic profile. *J. Am. Cardiol* 33:1294-1304.

David W., (1978) Winsor M.D., et al The natural course of arteriosclerosis in animals and man. *angiology* 29:263-271.

Davies MJ, Thomas AC. (1995). Plaque fissuring. The cause of acute myocardial infarction, sudden ischemic death and crescendo angina. *Br. Heart J.* 53:363-73.

Davies M, Martín T, Thomas GJ, Lovett DH. (1992) Proteinases and glomerular matrix turnover. *Kidney Int.* 41:671-678.

Davies MJ, (1996) Stability and instability: two faces of coronary atherosclerosis: The Paul Dudley White lecture 1995. *Circulation*. 94:2013-20

De Winther MP, Hofker MH (2000). Scavenging new insights into atherogenesis. *J. Clin. Invest.* 105:1039-1041.

Diamond y Karnovsky M.J. (1987). Exacerbation of chronic aminonucleoside nephrosis by dietary cholesterol supplementation. *Kidney Int.* 32:671-677.

Dominguez JH, Tang N, Xu W, Evan AP, Siakotos AN, Agarwal R, Walsh J, Deeg M, Pratt JH, March KL, Monnier VM, Weiss MF, Baynes

JW, Peterson R(2000) Studies of renal injury. III. Lipid-induced nephropathy in type II diabetes. *Kidney Int.*57:92-104.

Eddy AA. (1996) Interstitial inflammation and fibrosis in rats with diet induced hypercholesterolemia. *Kidney Int.* 50:1139-1149.

Ehrenstein MR, Jury EC, Mauri C.(2005) Statins for atherosclerosis as good as it gets? *N. Engl. Journ. Med.* 2005;352:73-5.

Eidelman RS, Lamas GA, Hannekens CH. (2002). The new National cholesterol Education program guidelines: Clinical changes for more widespread therapy of lipids to treat and prevent coronary heart disease. *Arch. Intern Med.* 162-2033

El Nahass AM, Basset AH, Cope GH.(1991) Role of growth hormone in the development of experimental renal scarring.*Kidney Intern.* 40: 29-34.

El Nahass AM. (2003) Kidney remodelling and scarring: the plasticity of cells. *Nephrol Dial Transplant.* 18:1959-1962.

Eriksson EE, Xie X, Werr J, Thoren P, Lindbom L. (2001) Importance of primary capture and L-selectin-dependent secondary capture in leukocyte accumulation in inflammation and atherosclerosis in vivo.*J. Exp. Med.* 194:205-18

Fabricant C.G. Fabricant J. Litrenta MM, Minick CR. (1978). Virus-induced atherosclerosis.*J. exp. Med* 148:335-340.

Falk E, Shah PK, Fuster V. Coronary plaque disruption. (1995) *Circulation.* 92:657-71.

Fernández-Varón E, Bermejo R, Ayala I, Tvarijonaviciuté A, cárceles C. (2005). Desarrollo y validación de una técnica de cromatografía líquida de alta resolución para la determinación de atorvastatina en plasma en un biomodelo experimental de arteriosclerosis en pollo. Clin. Invest. Arterioscl. 17(5):223-7.

Floege J. (2002) Nephron. 91(4):582-7.

Foley RN, Parfrey PS, Sarnak MJ. (1998). Cardiovascular disease in chronic renal disease: clinical epidemiology of cardiovascular disease in chronic renal disease. Am. Kidney Dis.32:S112-9

Fox H. 1933. Arterioesclerosis. Macmillan. New york. 250 pp.

French J.W, Yamanaka B.S. and Ostwald R. (1967). Dietary induced glomerulosclerosis in the guinea pig. Arch. Pathol. Lab. Med. 83: 204-210.

Fried L, Orchard T, Kasiske B. (2001). Effect of lipid reduction on the progression of renal disease:A meta-analysis.Kidney international. Vol. 59:260-269.

Gao P, Jia RH, Yang D, Liu H, Song E, Chu G, Ding G.(2005) Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats. Chin. Med. J .118(7):598-602.

García Pérez B. (1992). Efecto del nifedipino, verapamilo y diltiazem sobre la placa arteriosclerosa inducida experimentalmente en pollos alimentados con huevos. Tesis Doctoral. Universidad de Murcia.

García Pérez, B., Ortega, J.V., Fernández-Pardo, J., Valdés, M. (2002). Efecto antiaterogénico de la atorvastatina en pollos alimentados con una dieta rica en huevos. *Clín. Invest. Arteriosclerosis*. 782: 20-25.

García Pérez, B., Ayala, I., Castells, M.T., Madrid, J.F., Ortega, M.R., Ortega, J.V., Ballesta, J., Fernández Pardo, J., Valdés, M. (2003). Planimetric and histological study of the aorta in atherosclerotic chickens treated with nifedipine, verapamil and diltiazem. *Histol. Histopathol*. 18: 1027-1033.

García Pérez B, Ayala I, Doménech G, Sánchez Polo MT, García Partida P, Valdés M.(2005) Effects of nifedipine, Verapamil and Diltiazem on serum Biochemical parameters and aortic composition of atherosclerotic chickens. *Biomedicine and pharmacotherapy* 59:1-7.

Gassler,N, M. Elger, D.Inoue, W. Kriz and M. Amling.(1998) Oligonefronia not exuberant apoptosis, accounts for the development of glomeruloesclerosis, in the blc-2 knockout mouse. *Nephrol Dial Transplant*.13 : 2509-2518.

Gheith OA, Sobh MA, Mohamed LS, El Baz MA. (2002). Impact of treatment of dyslipidemia on renal function, fat deposits and scarring in patients with persistent nephrotic syndrome. *Ephron* 91(4):612-9.

Glagov S, Weisemberg E, Zarins CK. (1987). Compensatory enlargement of human artherosclerotics coronary arteries. *N. Engl. J. Med*.87, 316 (22):1317-5.

Glazer AA., Inman Sr, Stowe Nt, Novick AC. (1997) Renal microcirculatory effects of lovastatina in a rat model of reduced renal mass Urology. 50(5):812-7

Goldstein JL, Brown MS. Regulation of the mevalonate pathway.(1990) Nature. 343:425-30.

Goldstein J.L, Kita T. and Brown M.S. (1983). Defective lipoprotein receptors and atherosclerosis. Lessons from an animal counterpart of familial hypercholesterolemia. New Engl. J. Med. 309, 288-296.

Gómez-Gerique JA, Ros E, Oliván J, Mostaza JM, Villardel M, Pinto X, Civeira F, Hernandez A, da Silva PM, Rodríguez-Botaro A, Zambon D, Lima J, Diaz C, Aristegui R, Sol JM, Chaves J, Hernandez G Atomix investigators.(2002) Effect of atorvastatina and bezafibrato on plasma levels of C reactive protein on plasma mixed Hiperlipidemia. Atherosclerosis. 162:245-51.

Göran K, Hansson (2005) Inflammation, Atherosclerosis and coronary artery disease N Engl J Med 2005; 352: 1685-95.

Gotto AM. (2003) Risk and benefits of continue statin aggressive therapy.Clin Card. 26. III3-12.

Groene H. J.,Gotto, AM Jr. (2003) Safety and statin therapy: reconsiderin the risks and benefits. Arch Intern Med: 163-657

Groene E., Luthe H., Weber M.H. and Helmchen V. (1989), Induction of glomerular sclerosis by a lipid-rich diet in male rats. *Lab. Invest.* 60, 433-446.

Grond J., Van Goor H. And Elema J.D. (1986) Histochemical analysis of focal segmental hyalinosis and sclerosis lesions in various rats models of experimental nephrotic syndrome. *Kidney Int.* 29, 945-946.

Groene EF, Walli AK, Groene HJ, Miller B, Seidel D (1994) The role of lipids in nephrosclerosis and glomerulosclerosis. *Atherosclerosis* 107:1-13.

Guijarro C., Kim Y. (1996). Lovastatin inhibits lipopolysaccharide induced NF- κ B activation in human mesangial cell. *Nephrol dial traspl.* 11:990-996

Hafez KS., Inman SR., Stowe NT.(1996) Renal hemodynamic effects of lovastatin in a renal ablation model. *Urology.* 48(6):862-7.

Haller H.(1997) Endothelial function: general considerations. *Drugs.* 53:1-10.

Hansson GK, Holm J, Johansson L.(1989) Detection of activated T lymphocytes in the human atherosclerotic plaque. *Am. J. Pathol.*135:169-75.

Hansson GK.(2005) Inflammation, atherosclerosis and coronary artery disease. *N Engl. J Med.*352:1685-95.

Hashimoto H.,Kitagawa K, Hougaku H, Etani H, Hori M. (2001) C-reactive protein is an independent predictor of the rate of increase in early carotid atherosclerosis. *Circulation.* 104:63-7.

Hattori M, Nikolic-Paterson DJ, Miyazaki K, Isbel NM, Lan HY, Atkin RC, Kawaguchi H, Ito K. (1999) Mechanisms of glomerular macrophage infiltration in lipid-induced renal injury. *Kidney Int. Suppl.* 71:S47-S50.

Haynes WG, Web DJ. (1998) Endothelin as a regulator of cardiovascular function in health and disease. *J. Hipertens.* 16:1081-98.

Heagerty AM, Aalkjaer C, Bund SJ, Korsgaard N, Mulvany Mj. (1993). Small artery structure in Hypertension. Dual process of remodelling and growth. *Hypertension.* 21:391-97.

Heinecke JW, Suits AG, Aviram M, Chait A. (1991) Phagocytosis of lipase-aggregated low-density lipoprotein promotes macrophage foam cell formation: Sequential morphological and biochemical events. *Arterioscler Thromb.* 11:1643-1651.

Hernandez - Presa MA, Bustos C, Ortego M, Tuñón J, Renedo G, Ruiz-Ortega M. (1997) Angiotensin-converting enzyme inhibition prevents arterial nuclear factor- κ B activation, monocyte chemoattractant protein-1 expression, and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. *Circulation.* 95:1532-1541.

Heusinger-Riveiro J., Fischer B, Goppelt-Struebe M. (2004) Differential effects of simvastatin on mesangial cells. *Kidney Int.* 66 (1): 187-95.

Horlyck L., Katz L. (1949) Retrogression of atherosclerotic lesions on cessation of cholesterol feeding in the chick. *J.Lab.Cli.Med.* 34:1427-1472.

Hovig T, Blomhoff J.P., Holme R., Flatmark A. and Gjone E. (1978).

Plasma lipoprotein alterations and morphologic changes with lipid deposition in the kidneys of patients with hepatorenal syndrome. *Lab. Invest* 38: 540-549.

Hovig T and Gjone E (1974). Familial lecithin cholesterol acyltransferase deficiency. Ultrastructural studies on lipid deposition and tissue reactions. *Scand. J. Clin. Lab. Invest.* 33(137):135-146.

Huang WM, Gibson SJ, facer P, gu J, Polak JM (1983). Improved section adhesion for immunocytochemistry using high molecular weight polymers of L_lysine as a slide coating. *Histochemistry* 77,275-277.

Ignatowssky A. (1908). Wyrkung der tierischen nahrung auf den kaninchen-organismun. *Ver. D. mil. Mediz Akad.* 16: 174-180.

Intengan H, Schiffrin E. (2001). Vascular remodelling in Hypertension. Roles of apoptosis, inflammation and fibrosis. *Hypertension* 38(2):581-287.

Ikeuchi H., Kuroiwa T, Yamashita S, Kobayasy S, Kaneko Y. (2004) Fluvastatin reduces renal fibroblasl proliferation and production of type III collagen:Therapeutic implications for tubulointerstitial fibrosis. *Nephron. Exp. nephrol.* 97 (4) e115-22.

Inman SR., Davis NA, Olson KM.(2003) Simvastatin attenuates renal ischemia/reperfusion injury in rats administred cyclosporine A. *Am. J. Med. Sci.*326(3): 117-21

Inman SR., Davis NA, Mazzone ME. (2005) Simvastatin and L-Arginine preserve renal function after ischemia /reperfusion injury. *Am. J. Med. Sci.* 329(1) 13-7.

Inoue I, Goto S, Mizotani K, Awata T, Mastunaga T, Kawai S. (2000) Lipophilic HMG-Co A reductasa inhibitor has an antiinflamatory effect: reduction of mRNA levels for Interleukin-Beta , Interleukin-6, Cyclooxygenase 2 and pp22phox by regulation of peroxisome proliferators-activated receptor alpha in primary endothelial cells. *Life Sci.* 67:863-76.

Ionescu E, Sauter JF, Jeanrenaud B. (1985) abnormal oral glucose tolerance in genetically obese (fa/fa) rats. *Am. J. Physiol.* 248: E500-E506.

Islam KH, Khan MZ, Siddiqui MS, Islam MR, Lucky NS, Hossain MK, Adhikary GN. (2004). The anatomical studies of the kidneys of Rhode Island Red (RIR) and white leghorn chicken during their postnatal stages of growth and development. *Int. J. poultry scien.* 3(5):369-372.

Jandeleit-Dahm K., Cao Z, Cox AJ, Kelly DJ, Gilbert RE, Cooper ME. (1999) Role of hiperlipidemia in progressive renal disease: focus on diabetic nephropaty. *Kidney Int. sup.* 71:S31-6.

Jiang J., Roman RJ. (1997) Lovastatina prevents development of hypertension in spontaneously hypertensive rats. *Hypertension.* 30 (4):968-74

Johnson AC, Yabu JM, Hanson S, Shah VO, Zager RA. (2003) Experimental glomerulopathy alters renal cortical cholesterol, SR-B1, ABCA1, and HMG CoA reductase expression. *Am. J. Pathol.* 162:283-291.

Joles JA, Kunter U, Janssen U, Kriz W, Rabelink TJ, Koomans HA, Floege J.(2000) Early mechanisms of renal injury in hypercholesterolemic or hypertriglyceridemic rats. *J.Am. Soc. Nephrol.* 11:669-683.

Kagota S, Yamaguchi, Nakamura K, Kunimoto M. (2000).Functional evidence for antioxidant action of fluvastatin on low density lipoprotein using isolated macrophages and aorta. *Clin Exp Pharmacol Physiol.*27:401-5.

Kamanna V.S., Pai R., Roh D.D. and Kirschenbaum M.A. (1996).Oxidative modification of low-density lipoprotein enhances the murine mesangial cell cytokines associated with monocyte migration, differentiation and proliferation. *Lab. Invest* 74, 1067-1079.

Kamanna V.S, Pai R., Bassa B. and Kirschenbaum M.A. (1996). Activation mesangial cell with TNF- α stimulates M-CSF gene expression and monocyte proliferation. Evidence for the involvement of Protein kinase C and protein tyrosine kinase. *Byochem. Byophys. Acta* 1313,161-172.

Kamanna V.S., Kashyap M.L., Pai R., Bui D.T., Jin F., Roh D.D., Shah G.M. and Kirschenbaum M.A. (1994). Uremic serum subtracts inhibits apoprotein A-I production by a human hepatoma cell line. *J. Am. Soc. Nephrol.* 5, 193-200.

Kamanna V.S., Roh D.D. and Kirschenbaum M.A. (1993). Atherogenic lipoproteins mediators of glomerular injury. Am. J. Nephrol. 13,1-5.

Kamanna V.S. and Kirschenbaum M.A (1993). Asociation between very-low density lipoprotein and glomerular injury in obese zucker rats. Am J Nephrol. 13: 53-58.

Kano H, Hayashi T, Sumi D, Esaki T, Asai Y, Thakur NK. (1999). A HMGCo-A reductasa inhibitor improve regression of atherosclerosis in the rabbit aorta without affecting serum lipid levels: posible relevante of up-regulation of endothelial NO synthasa mRNA. Biochem. Biophys. Res. Commun. 259:414-19.

Kasiske B.L., Cleary M.P., O'Donnell M.P. and Keane W.F. (1985).

Effects of genetic obesity on renal structures and function in the Zucker rat. J. Lab. Clin. Med. 106,598-604.

Kasiske BL., O'Donnell MP., Keane WF (1990) The obese zucker rat model of glomerular injury in type II diabetes.J Diabetic complications 1:26-29

Kasiske BL, O'Donnell MD, Cleary MP, Keane WF. (1998) Treatment of hyperlipidemia reduces glomerular injury in obese Zucker rats. Kidney Int. 33:667-672.

Kasiske BL, Heim-Duthoy KL .(2001) The effects of lipid-lowering agents on acute renal allograf rejection.Transplantation 72:223-227.

Keane WF, Kasiske BL, O'Donnell MP. (1988) Lipids and progressive glomerulosclerosis: A model analogous to atherosclerosis. *Am.J. Nephrol.* 8:261-271.

Keane WF. (2003) The role of lipids in renal disease: Future challenges. *Kidney Int.* 57:S27-S31.

Keane WF, Mulcahy WS, Kasiske BL.I (1991) Hyperlipemia and progressive renal disease. *Kidney international.* 39 (31):S41-S48.

Keane WF, Kasiske B, O'Donnell MP, Kim Y. (1993) Hypertension, hyperlipidemia and renal damage. *Am. J. Kidney Dis.* 21 (2):43-50.

Keane WF, Kasiske B, O'Donnell MP, Kim Y. (1991).The role of altered metabolism in the progression of renal disease experimental evidence. *Am. J. Kidney Dis.*17(1): 38-42.

Keane WF. (2000). The role of lipids in renal disease: future challenges. *Kidney int.* 57:27-31.

Kees-Folts D, Diamond JR. (1993) Relationship between hyperlipidemia, lipid mediators, and progressive glomerulosclerosis in the nephrotic syndrome. *Am J Nephrol.* 13:365-375.

Kido M, Ando K, Oba S, Fujita T. (2005) Renoprotective effect of pravastatin in salt-loaded Dahl salt-sensitive rats. *Hypertens Res.*28(12):1009-15.

Kim SY, Guijarro C, O'Donnell MP, Kasiske WF. (1995). Human mesangial cell production of monocyte chemoattractant protein-1: modulation by lovastatin. *Kidney Int* .48:363-371.

Kimmelstiel P. and Wilson C. (1936). Intercapillary lesions in the glomerulus of the kidney. *Am. J. Pathol.* 12, 83-98.

Kovanen PT, Kaartinen M, Paavonen T. (1995) Infiltrates of active mass cells at the site of coronary atheromatous eruption or rupture in myocardial infarction. *Circulation.* 92:1084-8.

Lacoste L, Lam JY, Hung H, Letchacovsky G, Solymoss CB, Waters D. (1995). Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction. *Circulation.*92:3172-7.

Lahera WG, de las Heras N, Vazquez-Cruz B, Oubiña MP, Cachofeiro V. (2001). Endotelio vascular: factores y funciones. Disfunción endotelial. En Lahera editor. Lesión endotelial en la patología vascular. Madrid: SCM 13-30

Lambert G., Sakai N., Vaisman. (2001). Analysis of glomerulosclerosis and atherosclerosis in lecithin cholesterol acyltransferase- deficient mice *The Journal of biological chemistry* Vol. 276. Nº 18, pp.15090-15098, 2001

Lavaud S, Michel O, Sassy-Prigent C, Heudes D, Bazin R, Bariety J, Chevalier J. (1996). Early influx of glomerular macrophages precedes glomerulosclerosis in the obese Zucker rat model. *J. Am. Soc. Nephrol.* 7:2604-2615. 67

Lee SK., Jin SY, Hang DC, Hwang SD.(1993). Effects of delayed treatment with enalapril and/or lovastatina on the progression of glomerulosclerosis in 5/6 nephrectomized rats. *Nephrol. Dial. Transplant.* 8(12)1338-43.

Lee HS., Kim YS. (1998) Identification of oxidized low density lipoprotein in human renal biopsies. *Kidney international*, 54: 848-856.

Leitinger N.(2003). Oxidized phospholipids as modulators of inflammation in atherosclerosis. *Curr.Opin. Lipidol.* 14:421-30

Lemos PA, Serruys PW, De Feyter P, Mercado N, Goedhart D. (2005) Long term fluvastatin reduces the hazardous effect of renal impairment on four year atherosclerotic outcomes (a LIPS substudy). *Am J Cardiol.* 95:445-51.

Levy RI (1994). A quarter century of drug treatment of dyslipoproteinemia, with a focus on the new HMG-CoA reductase inhibitor fluvastatin *Circulation* 87:III45.

Li C, Lim SW, Yang CW, Park JH, Lim SW, Sun BK, Yung JY.(2005) Inhibitory effect of pravastatin on transforming growth factor beta1-inducible gene h3 expression in a rat model of chronic cyclosporine nephropaty. *Am. J. Nephrol.* 2005 25 (6):611-20.

Li H, Freeman MW, Libby P.(1995). Regulation of smooth muscle cell scavenger receptor expression in vivo by atherogenic diets and in vitro by cytokines. *J. Clin. Invest.* 95:122-8.

Li Z, Froelich J, Galis ZS, Lakatta EG, (1999). Increased expression of matrix metalloproteinase-2 in the thickened intima of aged rats. *Hypertension*.33:116-23.

Lijnen HR. Matrix metalloproteinases and cellular fibrinolytic activity. *Biochem*.67:92-8.

Liu J, Sukhova GK, Sun JS, Xu Wh. (2004). Lysosomal cysteine proteinases in atherosclerosis. *Arteriosc, Thromb. Vasc. Biol.* 24:1359-66.

Loftus IM, Naylor AR, Bell PRF, Thompson MM. (2002). Matrix metalloproteinases and atherosclerotic plaque instability. *Br. J. Surg.* 89:680-94.

Longo GM, Xiong W, Greiner TC, Zhao y, Fiotti N, Eaxter ET.(2002) Matrix metalloproteinase 2 and 9 work in concert to produce aortic aneurysms. *J. Clin. Invest.* 110:625-32.

López Fernández V, Suárez García S, Díaz González L, Alvarez Cosmea A, Arias García MT, Alvarez menendez F. (2006). Relación entre la proteína C reactiva ultrasensible y el síndrome metabólico en una población semiurbana española. *Clin. Invest. Arteriosc*.18:75-81.

Lovet Dh,Johnson RG, Marti HP, Martin J, Davies M, Couser EG. (1992).Structural characterization of the mesangial cell type-IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. *Am. J. Pathol.* 141:85-89.

Lu J, Bankovic-Calic N, Ogborn M, Saboorian MH, Aukema HM.(2003) Detrimental effects of a high fat diet in early renal injury are ameliorated by fish oil in Han:SPRD-cy rats. *J. Nutr.*133:180-186.

Lucas A, Dai E, Liu LY, Nation PN.(1998) Atherosclerosis in Marek's disease virus infected hypercholesterolemic roosters is reduced by HMGCoA reductase and ACE inhibitor therapy. *Cardiovasc. Res.* 38: 237-46.

Lynn E., Siow Y, Karmin O. (2000). Very low-density lipoproteins stimulates the expression of monocyte chemoattractan protein-1 in mesangial cells. *Kidney International.* 57: 1472-1483.

McCarey DW, McInness IB, Madhok R, Hampson R, Scherbakov S. (2004). Trial of atorvastatin in Rheumatoid arthritis (TARA): double blind randomised placebo-controlled trial. *Lancet.* 363:2015-21.

Maddox DA, Alavi FK, Santella RN, Zawata ET Jr. (2002). Prevention of obesity-linked renal disease: Age-dependent effects of dietary food restriction. *Kidney Int.* 62:208-219.

Maeso R, Aragoncillo P, Navarro-Cid J, Ruilope LM, Diaz C, Hernandez G, Lahera V, Cachofeiro V.(2000). Atorvastatin reduces endothelium-dependent constrictor factors in dyslipemic rabbits *Gen Pharmacol.* 34 (4): 263-72.

Martín Castillo A, Garcia Pérez B, Ayala I, Adánez G, Ortega JV, Sánchez MT, Castells MT. (2005) Evaluación macroscópica y microscópica del efecto de la atorvastatina sobre la regresión-progresión

de la esteatosis hepática en un modelo aviar. Clin. Invest. Arteriosc. 17(6): 270-277.

Martinez Castelao (2005). Seguridad de las estatinas en el paciente con insuficiencia renal. Clin Invest Arteriosc. 2:83-92

Martoja R, Martoja M. (1970) Técnicas de histología animal. Toray-Masson, Barcelona.

Massberg S, Brand K, Gruner S. 2002. A critical role of platelet adhesion in the initiation of atherosclerotic lesion formation. J. Exp. Med. 196:887-96.

Massy ZA, Ma JZ, Luo TA, Kasiske BL. (1995). Lipid-lowering therapy in patients with renal diseases. Kidney Int. 48:188-98.

Massy ZA., Guijarro C, O'Donnell MP., Kasiske BL., Keane WF. (1997). Lipids 3-hidroxy-3methylglutaryl coenzyme A reductasa inhibitors, and progression of renal failure. Adv. Nephrol. Necker Hosp.27:39-56.

Massy ZA, Kim K, Guijarro C, Kasiske WF, O'Donnell MP. (2000). Low-density lipoprotein-induced expression of interleukin-6, a marker of mesangial cell inflammation: effects of oxidation and modulation by lovastatina. Biochem. Biophys. Res. Commun. 267:536-540.

Michihara A, Akasaki K, Yamori Y, T Suji H. (2003). Change in the protein level of mevalonate pirofosfato decarboxilase in tissues of Mouse by pravastatin. Biol. Pharm. Bull. 26(8):1082-5.

Mizuguchi Y, Miyajima A, Kosaka T, Asano T, Hayakawa M. (2004) Atorvastatin ameliorates renal tissue damage in unilateral ureteral obstruction. *J. Urol.* 172: 2456-9.

Moorhead J.F., Chan M.K., El-Nahas M and Varghese Z. (1982). Lipid nephrotoxicity in chronic progressive glomerular and tubulointerstitial disease. *Lancet* 1, 1309-1311.

MRC/BHF Heart protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomised placebo controlled trial. *Lancet* 2002; 360-367

Munk F. (1916). Berichte Uber Krankheitslalle, Behandlung Verfahren. *Med. Klin.* 12: 1019-1076.

Murray CJ, López AD. (1997). Global mortality, disability, and the contribution to risk factors: Global burden of disease study. *Lancet.* 349:1436-42.

Muntner PM, Coresh J, Klag MJ, Smith JC, Eckfeldt J. (1998). Lipids and incipient hypercreatinemia: A prospective association. *J Am Soc Nephrol* 9: 617.

Newburger RA. and Peters J.P. (1939). Intercapillary glomerulosclerosis, a syndrome of diabetes, hypertension, and albuminuria. *Arch. Intern. Med.* 64,1252-1264.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD. (2005). Statin Therapy LDL cholesterol and C-Reactive protein, and coronary artery disease. *N. Engl. J. Med.* 352:29-38

Nöel LH. (1999). Morphological features of primary focal and segmental glomerulosclerosis. *Nephrol. Dial. Transplant.* 14(3):53-57.

Norman JT, Lewis MP. (1996). Matrix metalloproteinases in renal fibrosis. *Kidney int.* 54:61-3.

O'Brien KD, Alpers CE, Hokanson JE. (1996) Oxidation-specific epitopes in human coronary atherosclerosis are not limited to oxidized low-density lipoprotein. *Circulation* 94:1216-1225.

Oda H, Keane WF (1999). Recent advances in statins and the kidney. *Kidney Int. Suppl.* 71:S2-S5.

O'Donnell MP, Kasiske B, Cleary MP, Keane WF. (1985) Effects of genetic obesity on renal structure and function in the Zucker rat II. Micropuncture studies. *J. Lab. Clin. Med.* 106: 605-610.

O'Donnell MP, Kasiske B, Keane WF. (1993) Lovastatin retards the progression of established glomerular disease in obese Zucker rats. *Am. J. Kidney Dis.* 22(1):83-9.

O'Donnell MP, Kasiske B, Keane WF. (1993). Lovastatin inhibit the proliferation on rats mesangial cells. *Clin. Inves.* 91:83-87.

O'Driscoll G, Green D, Taylor RR. (1997) Simvastatin, a HMGCoA reductase inhibitor improves endothelial function within one month. *Circulation* 95:1126-1131.

Ohta Y, Yamamoto S, Tsuchida H, Murano S, Saitoh Y, Tohjo S, Okada M. (1986). Nephropathy of familiar lecithin-cholesterol acyltransferase deficiency, a case report. *Am. J. Kidney Dis*: 7, 41-46.

Orita, S., Masegui, T., Itou, K., Kawada, M., Yanai, T., Ueda, K. (1994). Spontaneous Aortic Arteriosclerosis in Layer Chickens. *J.Comp. Pathol.* 110: 341-347.

Ortega, J.V. (2002). Efecto de la atorvastatina en pollos aterogénicos alimentados con una dieta rica en huevos. Tesis Doctoral. Universidad de Murcia.

Ortega JV, García-Pérez B, Fernández Pardo J, Castells MT, Escobar S, Valdés M.(2002). Efecto antiaterogénico de la atorvastatina en pollos alimentados con una dieta rica en colesterol. *Clin. Invest. Arterioscl.*14(5):225-9.

Ortega JV. Ayala I, García Pérez B, Sánchez Polo MT, Castells MT.(2004) Uso de estatinas en biomodelos experimentales de arteriosclerosis. *An. Vet. Murcia.* 20: 49-57.

Oubiña P, de las Heras N, Vazquez-Pérez S, Cediél E, Sanz-Rosa D, Navarro-Cid J. (2001). Effects of quinqpril and atorvastatin on fibrinolytic balance on atherosclerotic rabbits. Abstract P3.152. Milan 11th European Meeting of Hypertension.

Páramo, J.A. I. Montero, J.A. Rodríguez y J. Orbe. (2005) Metaloproteinasas en aterosclerosis implicaciones fisiopatológicas y terapéuticas. Clin. Invest. Arterioscl. 17 (3): 133-41.

Piedagnel R, Murphy G, Ronco PM, Legont B. (1999) Matrix Metalloproteinase 2 (MMP2) and MMP9 are produced by kidney collecting duct principal cells but are differentially regulated by SV40 large T arginine vasopressin, and epidermal growth factor. J Biol Chem 274(3):1614-20.

Praga M (2005) Therapeutic measures in proteinuric nephropatic. Kidney Int. 99:S137-41.

Randall CJ, Reece R (1996).Color atlas of Avian histopathology.Mosby-Wolfe.

Raj L., Tollins J.P. and Luseher T. (1988). Hyperlipidemia and renal injury. Studies in atherosclerosis prone Watanabe rabbits with hereditary hyperlipidemia. Kidney Int. 33: 383A.

Ravanti L, Kahari V.M, (2000). Matriz metalloproteinases in wound repair.Int. J. Mol. Med.

Ridker PM, Rifai N, Clearfield M, Downs JR, Weis SE, Miles JS. Airforce Texas Coronary arteriosclerosis prevention Study investigators. (2001). Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N. Engl. J. Med.347:1959-65.

Ridker PM, Rifai N, Lowenthal SP. (2001). Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. *Circulation*. 103:1933-1935.

Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH, Pfeffer NA, Braunwald E; Pravastatin or atorvastatina evaluation and infection therapy-Thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Investigators. (2005). C-reactive protein levels and outcomes after statin therapy. *N. Engl. J. Med.*352: 20-8.

Rogler G, Lackner KJ, Schmitz G. (1995). Effects of fluvastatin on growth of porcine and human vascular smooth muscle cells in vitro.*Am. J. Cardiol.*76(2):114A-116A.

Roman J, Ma TH, Frohlich B, Markham B. (1993). Clofibrate prevents the development of hypertension in Dahl-sensitive Rats. *Hypertension*.21:985-8.

Rosenson, Rs. (2004). Current overview of statin-induced myopathy. *Am. J. Med.*116-408.

Ruan X, Varghese Z., Powis S., Moorhead J F. (1999). Human mesangial cells express inducible macrophage scavenger receptor *Kidney Int.* 56: 440-451.

Ruan X, Varghese Z., Powis S., Moorhead J. (2001). Dysregulation of LDL receptor under the influence of inflammatory cytokines: A new pathway for foam cell formation. *Kidney int.* 60:1716-1725.

Ruan X, Moorhead J, Ray F. (2003). PPAR Agonists protect mesangial cells from interleukin 1b-Induced intracellular lipid accumulation by activating the ABCA 1 cholesterol efflux pathway. *J. Am. Soc. Nephrol.* 14: 593-600.

Rubin R, Silbiger S, Sabaly L, Neugarten J. (1994). Combined antihypertensive and lipid lowering therapy in experimental glomerulonephritis. *Hypertension.*23:92-95.

(4S) Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian simvastatin survival studies (4S), *Lancet* 1994. 344-1383.

Sabbatini M., Pisani A, Ucello F, Serio V, Seru R, Paterno R, Cianciaruso B, Fuijano G, Andreucci M. (2004). Atorvastatin improves the course of ischemic acute renal failure in aging rats. *J. Am. Soc. Nephrol.* 15 (4):901-9.

Salamonsen LA, Zhang J, Hampton A, Lathburg L. (2000). Regulation of metalloproteinases in human endometrium. *Human reprod.* 15:112-9.

Samuelsson O., Mulec H., Knight-Gibson.(1997) Lipoproteins abnormalities are associated with increased rate of progression of human chronic renal insufficiency. *Nephrol. Dial. Transplant.* (1997)12:1908-1915.

Sánchez RM., Laguna JC. (2003). Nuevos mecanismos moleculares de la atorvastatina. *Clin Invest Arteriosc.*15(2): 3-14.

Savill J. (1994) Apoptosis and the kidney. *J Am Soc Nephrol.*5:12-21.

Scoble JE. (1999) Atherosclerotic nephropathy. *Kidney Int.* 71:S106-S109.

Scribner B, Lidner A, Charra B, Sherrard BH.(1974). Acelerated atherosclerosis in prolonged maintenance haemodialysis. *N. Engl. J. Med.*290(13):697-701.

Schaefer L., Han X., Matzkies F, August C, Lorentz T, Schaefer RM.(1997). Differential regulation of glomerular gelatinase B (MMP-9) and tissue inhibitor of metalloproteinase-1 (TIMP-1) in obese Zucker rats. *Diabetología.* 40: 1035-1043.

Schiffrin E. (1992). Reactivity of small blood vessels in hypertension: Relation with structural changes. *Hypertension* 19(2).

Schwartz GG., Olsson AG, Ezekowitz MD, Ganz P, Oliver MF, Waters Z, Zehier A, Chaitman BR, Leslie S, Stem T. (2001). Effects of Atorvastatin on early recurrent ischemic event in acute coronary syndromes. Myocardial ischemia reduction with aggressive cholesterol lowering (MIRACL) Study investigators. *JAMA* 285:1711-1718.

Sidaway J., Davison R. (2004) Inhibitors of 3-HMGCo-A reductase reduce receptor-mediated endocytosis in opossum kidney cells. *Jam. Soc. Nephrol.* 15:2258-2265.

Siller, W.G. (1961). The pathology of experimental atherosclerosis in egg-fed fowls. *J. Atheroscl. Res.* 1: 189-204.

Skalen K, Gustafsson M, Rydberg EK, Hulten LM, Wiklund O, Inerarity TL, Boren J. (2002) Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. *Nature*. 417:750-4.

Smith JD, Trogan E, Ginsberg M, Grigaux C, Miyata M. (1995). Decreased atherosclerosis in mice deficient in both macrophage colony-stimulating factor (op) and apolipoprotein E. *Proc. Natl. Acad. Sci. USA* 92:8264-8.

Song GW, Li C, Zheng YC, Kong J, Sun B. (2003). The expression of connective tissue growth factor in renal cortex of 5/6 nephrectomized rats its modulation by fluvastatin. *Zhonghua Yi Xue Za Zhi*. 83 (16) 1428-32.

Song Y., Li C., Cai L. (2004) Fluvastatin prevents nephropathy likely through suppression of connective tissue growth factor-mediated extracellular matrix accumulation. *Expl. mol. Pathol.* 76 (1) 66-75.

Stanler J, Wenworth D, Neaton JD. (1986). Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screeners of the MRFIT trial. *JAMA*. 256:2823-8.

Stary HC, Chandler AB, Dinsmore RE, Fuster V, Glagov S, Insull W, Rosefeld ME, Schwartz C, Wagner W, Wissler R. (1995). A definition of advanced types of atherosclerosis lesions and histological classification of atherosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis American Heart Association. *Circulation*. 92:1355-74

Stary HC, Chandler AB, Glagov S, Guyton Jr, Insull W, Rosenfeld MJ, Schwartz C, Wagner W, Wissler R. (1994) et al. A definition of initial, fatty streak and intermediate lesions of arteriosclerosis: a report from the committee on vascular lesions of the council on arteriosclerosis; American Heart Association. *Circulation*. 89:2462-78.

Stevenson FT, Kayser GA. (1999). Hyperlipidemia and renal disease: The use of animal models in understanding pathophysiology and approaches to treatment. *Wien Klin Wochenschr*. 111 (8): 307-14.

St Clair R.W. (1998). The contribution of avian models to our understanding of atherosclerosis and their promise for the low density lipoprotein and glomerular injury in obese Zucker rats. *Am. J. Nephrol*. 13:53-58.

Studer RK, Negrete H, Craven PA, DeRubertis FR. (1995). Protein kinase C signals thromboxane-induced increases in fibronectin synthesis and TGF- β bioactivity in mesangial cells. *Kidney Int*. 48:422-430.

Svueling EM, Hillege HM, Bakker SJ, Gans RO. (2003) C-Reactive protein is associated with renal function abnormalities in non-diabetic population. *Kidney int*. 63(2): 654-61.

Sumi D, Hayashi T, Thakur NK, Jayachandran M, Asai Y, Kano H.A. (2001). HMGCo-A reductase inhibitor possesses a potent antiatherosclerotic effect other than serum lowering lipid effects. The relevance of endothelial nitric oxide synthase and superoxide anion scavenging action. *Atherosclerosis*. 155:347-57.

Takemoto M, Liao JK.(2001).Pleiotropic effects of 3-Hidroxi-3-metylglutaryl coenzyme A reductase inhibitors. *Arteriosc. Thromb. Vasc. Biol.*21:1712-9.

Texon, M. (1960). The hemodynamic concept of atherosclerosis. *Am. J. Cardiol.* 5: 291-94.

Toda T, Leszczynski D, Kummerow F.(1981). Vasculotoxic effects of dietary testosterone, estradiol and cholesterol on chick artery. *J. Pathol.* 134 (3): 219-31

Tonelli M., Moye L., Sacks FM.(2003) Cholesterol and recurrent events CARE Trial investigators: Pravastatin for secondary prevention of cardiovascular events in persons with mild chronic renal insufficiency. *Ann. Intern. Med.*138:98-104.

Valdés Chavarri, M., Pascual-Leone, A., Oconnor, C. (1976). Verification of the cholesterol hypothesis in atherogenesis with a model of dietary atheromatosis in chicken fed with eggs. Influence of insulin and oral antidiabetics. *Rev. Clin. Esp.* 143(5): 427-35.

Van De Ree MA., Huisman MV, Princen HM, Meinders AE, Kluft C, Dali-Study group. (2003). Decrease of High sensitivity C-Reactive protein With high dose atorvastatin in patients with tipe II diabetes mellitus. *Atherosclerosis.* 166:129-35.

Van der Sande FM, Kooman JO, Leunissen KM. (2006). The predictive value of C-reactive protein in the end stage of renal disease: It is clinically significant ? *Blood Purif.* 24 (4):335-41.

Van der Wal AC, Becker AE, Van der Loos CM, Das PK. (1994) Site of intimal rupture or erosion of thrombosed coronary arteriosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology. *Circulation*. 89: 36-44.

Van Wissen S., Trip MD, Smilde TJ, de Graff J, Stalenhoef AF, Kastelein JJ. (2002). Differential PCR reduction in patients with hypercholesterolemia treated with statin therapy. *Atherosclerosis*. 165:361-6.

Vaugan CJ, Murphy MB, Buckley BM. (1996) Statins do more than just a lower cholesterol. *Lancet*. 348:1079-82.

Vazquez Pérez S, Aragoncillo P, de las Heras N, Navarro-Cid J, Cediél E, Sanz Rosa, Ruilope LM, Díaz C, Hernández G, Lahera V, Cachofeiro V. (2001). Atorvastatin prevents glomerulosclerosis and renal endothelial dysfunction in hypercholesterolemic rabbits. *Nephrol dial. Transp.*16(1):40-44.

Vieira JM., Mantovani E, Rodrigues LT, Delle H, Noronha IL, Fujihara CK, Zatz R. (2005). Simvastatin attenuates renal inflammation, tubular transdifferentiation and interstitial fibrosis en rat White unilateral ureteral obstruction *Nephrol. Dial. Transplant*. 20(8):1582-91

Vieira JM., Mantovani E, Rodrigues LT, Mattar AL, Delle H, Noronha IL, Fujihara CK, Zatz R. (2005). Statin monotherapy attenuates renal

injury in a SALT sensitive hypertension model of renal disease *Nephrol
physiol.*101 (4):82-91.

Virchow R. (1860). A more precise account of fatty metamorphosis. In:
Cellular pathology. 2nd ed. Gryphonham Gryphon Editions. England. 324-
366.

Wanner C, Krane V. (2002). Uremia-specific alterations in lipid
metabolism. *Blood Purif.* 20:451-453.

Washio M., Nanishi F, Onoyama K, Okuda S, Fujishima M.I (1993).
Effects of anti-hyperlipidemic agent or dietary protein restriction on
progressive renal deterioration in adryaycin-induced nephropaty in rats.
*Int. Urol. Nephrol.*25(3):295-303.

Weismantel,D.(2001) What laboratory monitoring is appropriate to detect
adverse drug reactions in patiens on cholesterol lowering agents?.*J. Farm.
Pract.* 50-927

Weiss, H.S. (1959). Variation in appeareance, cholesterol concentration
and weight of the chicken aorta with age and sex. *J. Gerontol.* 4: 19-25.

Wheeler DC. Statins and the kidney. *Curr Op Nephrol
Hyperrts.*1998;7:579-84.

Wheeler DC, Chana RS: Interactions between lipoproteins, glomerular
cells and matrix. *Miner Electrolyte Metab* 1993;19:149-164.

Wight P., Siller W. The histopathology of fatty liver and kidney syndrome in chicks. *Research in veterinary sciences* 1975,19,173-184.

Wilens S.L. and Elster SK (1951). The role of lipid deposition in renal arteriolar sclerosis. *Am. J. Med. Sci* 219, 183-196.

Wilson SH, Chade AR, Feldstein A, Sawamura T, Napoli C, Lerman A, Lerman LO. (2003). Lipid –lowering-independent effects of simvastatin on the kidney in experimental hipercholesterolaemia. *Nephrol. Dial. Transplant.* 18:703-709.

Winsor, D.W., Winsor T. y Maranga, K. (1978). The natural course of arteriosclerosis in Animals and Man. *Angiology* 29: 263-271.

Woessner JF (1992) Matrix metalloproteinases and their inhibitors in connective tissue remodelling. *FASEB J* 5:2145-2154.

Wong, H.Y. (1975). The cockerel as an animal model for atherosclerosis research. *Adv. Exp. Med. Biol.* 63: 381-387.

Yokoyama K, Sakai S, Sigematsu T, Takemoto F, Hara S, Yamada A, Kawaguchi Y, Hosoya T. (1998). LDL adsorption improves the response of focal glomerulosclerosis to corticosteroid therapy. *Clin Nephrol.* 50:1-7.

Yorioka N, Taniguchi Y, Nishida Y, Okushin S, Amimoto D, Yamakido A. (1997). Low-density lipoprotein apheresis for focal glomerular sclerosis. *Ther. Apher.* 1:370-371.

Yoshida Y, Fogo A, Ichikawa I.(1989) Glomerular hemodynamic changes vs hypertrophy in experimental glomerulosclerosis. *Kidney Int* 35: 654-660.

Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, Bravo M, Mitchel DJ, Sovel RA, Steinman L, Zamvil SS. (2002). The HMG-CoA reductasa inhibitor, atorvastatin promotes a Th-2 bias and reverses paralysis in central nervous system autoimmune disease. *Nature*. 420:78-84

Yu IH., Wang Y.(2005). Fluvastatin prevents renal injury and expression of lactin Like oxidized low density lipoprotein receptor-1 in rabbits white hypercholesterolemia *Chin. Med J. (eng)* 118 (88):621-6

Zager RA, Johnson A, Anderson K, Wright S. (2001). Cholesterol ester accumulation: An immediate consequence of acute in vivo ischemic renal injury. *Kidney Int*. 59:1750-1761.

Zager RA, Johnson A.(2001). Renal cortical cholesterol accumulation is an integral component of the systemic stress response. *Kidney Int*.60:2299-2310.

Zager RA, Johnson A, Hanson S, de la Rosa V. (2002). Altered cholesterol localization and caveolin expression during the evolution of acute renal failure. *Kidney Int*. 61:1674-1683.

Zhu B., Shen H, Zhou J, Lin F, Hu Y.(2005) Effects on simvastatin on oxidative stress in streptozotocin-induced diabetic rats: a role for glomeruli protection. *Nephron*. 101 (1) :1-8.

Zucker LM (1965) Hereditary obesity in the rat associated with hiperlipidemia. Ann.NY Acad. Sci. 131:447-458.